ClinicalTrials.gg
CompletedNCT01331681VIVID-DMEUpdated Nov 27, 2023Results posted

Intravitreal Aflibercept Injection in Vision Impairment Due to DME

A Phase 3 interventional study of VEGF Trap-Eye (BAY86-5321) and VEGF Trap-Eye (BAY86-5321) in Diabetes Mellitus and Macular Edema, sponsored by Bayer. Completed at 73 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-27.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
406
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Diabetes Mellitus by Bayer — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus · Bayer.

Started
2011
the only one that year
Phase 3
4 of 18
none open now
Registered
8th of 18
by date

Among the 18 studies in Diabetes Mellitus by Bayer, this one is the only one that started in 2011, is one of 4 in phase 3, and was the 8th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

None of the 18 studies in Diabetes Mellitus by Bayer is open now. The open studies under Diabetes Mellitus, anywhere →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies in Diabetes Mellitus by Bayer as a file.
02

Study summary

To determine the efficacy of intravitreally (IVT) administered VEGF Trap-Eye on the best-corrected visual acuity (BCVA) assessed by the early treatment diabetic retinopathy study (ETDRS) chart in subjects with diabetic macular edema (DME) with central involvement

03

Conditions studied

  • Diabetes Mellitus
  • Macular Edema

Keywords

  • Diabetic Macular Edema (DME)
  • VEGF Trap-Eye
  • Best-corrected visual acuity (BCVA)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥ 18 years with type 1 or 2 diabetes mellitus
  • Subjects with DME secondary to diabetes mellitus involving the center of the macula in the study eye
  • Decrease in vision determined to be primarily the result of DME in the study eye
  • BCVA ETDRS letter score of 73 to 24 (20/40 to 20/320) in the study eye

Exclusion criteria

Exclusion Criteria:

  • Laser photocoagulation (panretinal or macular) in the study eye within 90 days of Day 1
  • More than 2 previous macular laser treatments in the study eye
  • Previous use of intraocular or periocular in the study eye within 120 days of Day 1
  • Previous treatment with antiangiogenic drugs in either eye (pegaptanib sodium, bevacizumab, ranibizumab etc.) within 90 days of Day 1
  • Active proliferative diabetic retinopathy (PDR) in the study eye, with the exception of inactive, regressed PDR
  • Uncontrolled diabetes mellitus, as defined by > 12%
  • Only 1 functional eye even if that eye is otherwise eligible for the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
406 participants (actual)

Study arms

  • Experimental
    Intravitreal Aflibercept Injection 2Q4

    Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).

    Biological: VEGF Trap-Eye (BAY86-5321)

  • Experimental
    Intravitreal Aflibercept Injection 2Q8

    Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).

    Biological: VEGF Trap-Eye (BAY86-5321)

  • Active comparator
    Macular Laser Photocoagulation (Control)

    Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.

    Procedure: Macular Laser Photocoagulation (Control)

Interventions

  • Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).

  • Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).

  • ProcedureMacular Laser Photocoagulation (Control)

    Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in BCVA (Best Corrected Visual Acuity) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF)

    Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.

    Time frame: Baseline up to Week 52

Secondary outcomes

  1. Percentage of Participants Who Gained at Least 10 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF

    Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.

    Time frame: Baseline up to Week 52

  2. Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF

    Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.

    Time frame: Baseline up to Week 52

  3. Percentage of Participants With a ≥2-step Improvement From Baseline in the ETDRS DRSS (Diabetic Retinopathy Severity Score) as Assessed by FP (Fundus Photography) at Week 52 - LOCF

    Baseline ETDRS DRSS: None (level 10); Mild to moderate nonproliferative DR (levels 14, 15, 20, 35, and 43); Moderately severe/severe nonproliferative DR (levels 47 and 53); Mild/moderate/high-risk/advanced proliferative DR (levels 61, 65, 71,75, 81, and 85)

    Time frame: Baseline up to Week 52

  4. Change From Baseline in Central Retinal Thickness (CRT) at Week 52 as Assessed on Optical Coherence Tomography (OCT) - LOCF

    Time frame: Baseline up to Week 52

  5. Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Near Activities Subscale at Week 52 - LOCF

    The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf.

    Time frame: Baseline up to Week 52

  6. Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF

    The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Distance activities are defined as reading street signs or names on stores, and going down stairs, steps, or curbs.

    Time frame: Baseline up to Week 52

07

Results

Posted Sep 9, 2014

Participant flow

Participants with diabetic macular edema (DME) secondary to diabetes mellitus involving the center of the macula in the study eye could participate in the study. The study was conducted at 73 study centers in Japan, European Countries and Australia between 09 May 2011(first participant first visit) and 30 Mar 2015 (last participant last visit).

Participant flow — Overall Study
MilestoneIntravitreal Aflibercept Injection 2Q4Intravitreal Aflibercept Injection 2Q8Macular Laser Photocoagulation (Control)
Started136135135
Participants received treatment136135133
Completed week 52125121115
Completed week 100115110105
Completed week 148101101100
Completed101101100
Not completed353435
Withdrew: Adverse event101310
Withdrew: Death662
Withdrew: Lack of efficacy010
Withdrew: Withdrawal by subject12815
Withdrew: Protocol violation110
Withdrew: Lost to follow-up241
Withdrew: Physician decision204
Withdrew: Therapeutic procedure required100
Withdrew: Sponsor decision110
Withdrew: Switching to other therapy001
Withdrew: Not received study treatment002

Outcome measures

PrimaryChange From Baseline in BCVA (Best Corrected Visual Acuity) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF)

Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.

Time frame:
Baseline up to Week 52
Reported as:
Mean · Letters correctly read
Change From Baseline in BCVA (Best Corrected Visual Acuity) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF)
Letters correctly readIntravitreal Aflibercept Injection 2Q4Intravitreal Aflibercept Injection 2Q8Control
Change From Baseline in BCVA (Best Corrected Visual Acuity) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF)10.5 ± 9.5510.7 ± 9.321.2 ± 10.65
Statistical analysis
  • Intravitreal Aflibercept Injection 2Q4 vs Control · ANCOVA · p = <0.0001 (Significance level alpha=0.025 for two sided test to adjust for multiplicity. Since this p-value was below the significance level of 0.025, the fixed sequence testing did continue with the first secondary endpoint.) · Mean difference (final values): 9.3 · 97.5% CI 6.5 to 12.0Least square (LS) mean difference from ANCOVA. The estimate is calculated as EYLEA minus Laser. A positive value indicates a result in favor of EYLEA.
  • Intravitreal Aflibercept Injection 2Q8 vs Control · ANCOVA · p = <0.0001 (Significance level alpha=0.025 for two sided test to adjust for multiplicity. Since this p-value was below the significance level of 0.025, the fixed sequence testing did continue with the first secondary endpoint.) · Mean difference (final values): 9.1 · 97.5% CI 6.3 to 11.8LS mean difference from ANCOVA. The estimate is calculated as EYLEA minus Laser. A positive value indicates a result in favor of EYLEA.
SecondaryPercentage of Participants Who Gained at Least 10 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF

Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.

Time frame:
Baseline up to Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Who Gained at Least 10 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF
Percentage of participantsIntravitreal Aflibercept Injection 2Q4Intravitreal Aflibercept Injection 2Q8Control
Percentage of Participants Who Gained at Least 10 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF54.453.325.8
Statistical analysis
  • Intravitreal Aflibercept Injection 2Q4 vs Control · Cochran-Mantel-Haenszel · p = <0.0001 (Significance level alpha=0.025 for two sided test to adjust for multiplicity. Since this p-value and the preceding ones were below the significance level of 0.025, the fixed sequence testing did continue with the second secondary endpoint.) · Cmh adjusted difference: 28.7 · 97.5% CI 15.8 to 41.6The estimate is calculated as EYLEA minus Laser. A positive value indicates a result in favor of EYLEA.
  • Intravitreal Aflibercept Injection 2Q8 vs Control · Cochran-Mantel-Haenszel · p = <0.0001 (Significance level alpha=0.025 for two sided test to adjust for multiplicity. Since this p-value and the preceding ones were below the significance level of 0.025, the fixed sequence testing did continue with the second secondary endpoint.) · Cmh adjusted difference: 27.5 · 97.5% CI 14.6 to 40.5The estimate is calculated as EYLEA minus Laser. A positive value indicates a result in favor of EYLEA.
SecondaryPercentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF

Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.

Time frame:
Baseline up to Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF
Percentage of participantsIntravitreal Aflibercept Injection 2Q4Intravitreal Aflibercept Injection 2Q8Control
Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF32.433.39.1
Statistical analysis
  • Intravitreal Aflibercept Injection 2Q4 vs Control · Cochran-Mantel-Haenszel · p = <0.0001 (Significance level alpha=0.025 for two sided test to adjust for multiplicity. Since this p-value and the preceding ones were below the significance level of 0.025, the fixed sequence testing did continue with the third secondary endpoint.) · Cmh adjusted difference: 23.3 · 97.5% CI 12.6 to 33.9The estimate is calculated as EYLEA minus Laser. A positive value indicates a result in favor of EYLEA.
  • Intravitreal Aflibercept Injection 2Q8 vs Control · Cochran-Mantel-Haenszel · p = <0.0001 (Significance level alpha=0.025 for two sided test to adjust for multiplicity. Since this p-value and the preceding ones were below the significance level of 0.025, the fixed sequence testing did continue with the third secondary endpoint.) · Cmh adjusted difference: 24.2 · 97.5% CI 13.5 to 34.9The estimate is calculated as EYLEA minus Laser. A positive value indicates a result in favor of EYLEA.
SecondaryPercentage of Participants With a ≥2-step Improvement From Baseline in the ETDRS DRSS (Diabetic Retinopathy Severity Score) as Assessed by FP (Fundus Photography) at Week 52 - LOCF

Baseline ETDRS DRSS: None (level 10); Mild to moderate nonproliferative DR (levels 14, 15, 20, 35, and 43); Moderately severe/severe nonproliferative DR (levels 47 and 53); Mild/moderate/high-risk/advanced proliferative DR (levels 61, 65, 71,75, 81, and 85)

Time frame:
Baseline up to Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With a ≥2-step Improvement From Baseline in the ETDRS DRSS (Diabetic Retinopathy Severity Score) as Assessed by FP (Fundus Photography) at Week 52 - LOCF
Percentage of participantsIntravitreal Aflibercept Injection 2Q4Intravitreal Aflibercept Injection 2Q8Control
Percentage of Participants With a ≥2-step Improvement From Baseline in the ETDRS DRSS (Diabetic Retinopathy Severity Score) as Assessed by FP (Fundus Photography) at Week 52 - LOCF33.327.77.5
Statistical analysis
  • Intravitreal Aflibercept Injection 2Q4 vs Control · Cochran-Mantel-Haenszel · p = <0.0001 (Significance level alpha=0.025 for two sided test to adjust for multiplicity. Since this p-value and the preceding ones were below the significance level of 0.025, the fixed sequence testing did continue with the fourth secondary endpoint.) · Cmh adjusted difference: 25.8 · 97.5% CI 12.2 to 39.4The estimate is calculated as EYLEA minus Laser. A positive value indicates a result in favor of EYLEA.
  • Intravitreal Aflibercept Injection 2Q8 vs Control · Cochran-Mantel-Haenszel · p = 0.0006 (Significance level alpha=0.025 for two sided test to adjust for multiplicity. Since this p-value and the preceding ones were below the significance level of 0.025, the fixed sequence testing did continue with the fourth secondary endpoint.) · Cmh adjusted difference: 19.3 · 97.5% CI 6.6 to 32.1The estimate is calculated as EYLEA minus Laser. A positive value indicates a result in favor of EYLEA.
SecondaryChange From Baseline in Central Retinal Thickness (CRT) at Week 52 as Assessed on Optical Coherence Tomography (OCT) - LOCF
Time frame:
Baseline up to Week 52
Reported as:
Mean · micrometer
Change From Baseline in Central Retinal Thickness (CRT) at Week 52 as Assessed on Optical Coherence Tomography (OCT) - LOCF
micrometerIntravitreal Aflibercept Injection 2Q4Intravitreal Aflibercept Injection 2Q8Control
Change From Baseline in Central Retinal Thickness (CRT) at Week 52 as Assessed on Optical Coherence Tomography (OCT) - LOCF-195.0 ± 146.59-192.4 ± 149.89-66.2 ± 138.99
Statistical analysis
  • Intravitreal Aflibercept Injection 2Q4 vs Control · ANCOVA · p = <0.0001 (Significance level alpha=0.025 for two sided test to adjust for multiplicity. Since this p-value and the preceding ones were below the significance level of 0.025, the fixed sequence testing did continue with the fifth secondary endpoint.) · Mean difference (final values): -157.0 · 97.5% CI -190.9 to -123.1LS mean difference from ANCOVA. The estimate is calculated as EYLEA minus Laser. A positive value indicates a result in favor of EYLEA.
  • Intravitreal Aflibercept Injection 2Q8 vs Control · ANCOVA · p = <0.0001 (Significance level alpha=0.025 for two sided test to adjust for multiplicity. Since this p-value and the preceding ones were below the significance level of 0.025, the fixed sequence testing did continue with the fifth secondary endpoint.) · Mean difference (final values): -142.8 · 97.5% CI -179.3 to -106.3LS mean difference from ANCOVA. The estimate is calculated as EYLEA minus Laser. A negative value indicates a result in favor of EYLEA.
SecondaryChange From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Near Activities Subscale at Week 52 - LOCF

The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf.

Time frame:
Baseline up to Week 52
Reported as:
Mean · Scores on a scale
Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Near Activities Subscale at Week 52 - LOCF
Scores on a scaleIntravitreal Aflibercept Injection 2Q4Intravitreal Aflibercept Injection 2Q8Control
Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Near Activities Subscale at Week 52 - LOCF5.73 ± 18.9325.29 ± 19.0583.54 ± 16.768
Statistical analysis
  • Intravitreal Aflibercept Injection 2Q4 vs Control · ANCOVA · p = 0.2208 (Significance level alpha=0.025 for two sided test to adjust for multiplicity. Since this p-value is not below of 0.025, the fixed sequence testing stops here. The sixth secondary endpoint cannot be tested confirmatory.) · Mean difference (final values): 2.41 · 97.5% CI -2.01 to 6.82LS mean difference from ANCOVA. The estimate is calculated as EYLEA minus Laser. A positive value indicates a result in favor of EYLEA.
  • Intravitreal Aflibercept Injection 2Q8 vs Control · ANCOVA · p = 0.5537 (Significance level alpha=0.025 for two sided test to adjust for multiplicity. Since this p-value is not below of 0.025, the fixed sequence testing stops here. The sixth secondary endpoint cannot be tested confirmatory.) · Mean difference (final values): -1.21 · 97.5% CI -5.79 to 3.37LS mean difference from ANCOVA. The estimate is calculated as EYLEA minus Laser. A positive value indicates a result in favor of EYLEA.
SecondaryChange From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF

The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Distance activities are defined as reading street signs or names on stores, and going down stairs, steps, or curbs.

Time frame:
Baseline up to Week 52
Reported as:
Mean · Scores on a scale
Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF
Scores on a scaleIntravitreal Aflibercept Injection 2Q4Intravitreal Aflibercept Injection 2Q8Control
Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF0.94 ± 16.4875.32 ± 18.4752.26 ± 15.923
Statistical analysis
  • Intravitreal Aflibercept Injection 2Q4 vs Control · ANCOVA · p = 0.5138 · Mean difference (final values): -1.19 · 97.5% CI -5.29 to 2.91LS mean difference from ANCOVA. The estimate is calculated as EYLEA minus Laser. A positive value indicates a result in favor of EYLEA.
  • Intravitreal Aflibercept Injection 2Q8 vs Control · ANCOVA · p = 0.8498 · Mean difference (final values): -0.37 · 97.5% CI -4.79 to 4.05LS mean difference from ANCOVA. The estimate is calculated as EYLEA minus Laser. A positive value indicates a result in favor of EYLEA.

Adverse events

Collected over For each subject from his first study drug injection until 30 days after the last study drug injection at the latest up to termination visit at Week 148. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intravitreal Aflibercept Injection 2Q4——117/136 (86%)
Intravitreal Aflibercept Injection 2Q8——122/135 (90.4%)
Macular Laser Photocoagulation (Control)——113/133 (85%)
Most frequent serious events
Showing 10 of 190
Most frequent serious events
EventIntravitreal Aflibercept Injection 2Q4Intravitreal Aflibercept Injection 2Q8Macular Laser Photocoagulation (Control)
CataractEye disorders5/1367/1352/133
Myocardial infarctionCardiac disorders4/1361/1351/133
Vitreous haemorrhageEye disorders4/1361/1352/133
Cerebrovascular accidentNervous system disorders4/1361/1351/133
Acute myocardial infarctionCardiac disorders2/1360/1353/133
Retinal neovascularisationEye disorders1/1360/1353/133
Peripheral arterial occlusive diseaseVascular disorders1/1362/1353/133
PneumoniaInfections and infestations1/1363/1350/133
Humerus fractureInjury, poisoning and procedural complications3/1361/1350/133
Cataract operationSurgical and medical procedures3/1361/1352/133
Most frequent other events
Showing 10 of 41
Most frequent other events
EventIntravitreal Aflibercept Injection 2Q4Intravitreal Aflibercept Injection 2Q8Macular Laser Photocoagulation (Control)
Conjunctival haemorrhageEye disorders43/13639/13517/133
NasopharyngitisInfections and infestations38/13639/13534/133
Visual acuity reducedEye disorders33/13633/13530/133
Diabetic retinal oedemaEye disorders33/13623/13518/133
Visual acuity tests abnormalInvestigations19/13622/13532/133
CataractEye disorders31/13626/13517/133
Intraocular pressure increasedInvestigations28/13618/13516/133
Retinal haemorrhageEye disorders21/13625/13521/133
HypertensionVascular disorders23/13625/13524/133
Macular oedemaEye disorders21/13620/13522/133

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Intravitreal Aflibercept Injection 2Q4Intravitreal Aflibercept Injection 2Q8ControlTotal
Mean62.6 ± 8.664.2 ± 7.863.9 ± 8.663.6 ± 8.3
Sex: Female, Male
Sex: Female, Male(Participants)Intravitreal Aflibercept Injection 2Q4Intravitreal Aflibercept Injection 2Q8ControlTotal
Female534754154
Male838879250
08

Study locations

73 sites
  • Sydney, New South Wales 2000, Australia
  • Westmead, New South Wales 2145, Australia
  • East Melbourne, Victoria 3002, Australia
  • Nedlands, Western Australia 6009, Australia
  • Parramatta, 2150, Australia
  • Linz, Oberösterreich 4020, Austria
  • Linz, 4021, Austria
  • Wien, 1090, Austria
  • Faculty Hospital Hradec Kralove
    Hradec Kralove, 500 05, Czechia
  • Olomouc, 779 00, Czechia
  • Ostrava, 708 52, Czechia
  • Praha 10, 100 34, Czechia
  • Glostrup, 2600, Denmark
  • Århus C, 8000, Denmark
  • Bordeaux, 33076, France
  • Creteil Cedex, 94010, France
  • Lyon, 69003, France
  • Nantes Cedex, 44093, France
  • Hopital Lariboisiere
    Paris, 75010, France
  • Paris, 75015, France
  • Freiburg, Baden-Württemberg 79106, Germany
  • Heidelberg, Baden-Württemberg 69120, Germany
  • Tübingen, Baden-Württemberg 72076, Germany
  • München, Bayern 81675, Germany
  • Darmstadt, Hessen 64297, Germany
  • Göttingen, Niedersachsen 37075, Germany
  • Aachen, Nordrhein-Westfalen 52074, Germany
  • Bonn, Nordrhein-Westfalen 53105, Germany
  • Köln, Nordrhein-Westfalen 50924, Germany
  • Klinikum der Stadt Ludwigshafen am Rhein gGmbH
    Ludwigshafen, Rheinland-Pfalz 67063, Germany
  • Mainz, Rheinland-Pfalz 55131, Germany
  • Kiel, Schleswig-Holstein 24105, Germany
  • Berlin, 12203, Germany
  • Budapest, 1083, Hungary
  • Budapest, 1106, Hungary
  • Budapest, 1133, Hungary
  • Debrecen, 4032, Hungary
  • Veszprem, 8200, Hungary
  • Zalaegerszeg, H-8900, Hungary
  • Roma, Lazio 00133, Italy
  • Roma, Lazio 00198, Italy
  • Milano, Lombardia 20157, Italy
  • Ancona, Marche 60126, Italy
  • Padova, Veneto 35128, Italy
  • IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico
    Milano, 20122, Italy
  • Nagoya, Aichi 466-8560, Japan
  • Nagoya, Aichi 467-8602, Japan
  • Asahikwa, Hokkaido 078-8510, Japan
  • Sapporo, Hokkaido 060-8648, Japan
  • Kawasaki, Kanagawa 216-8511, Japan
  • Sendai, Miyagi 980-8574, Japan
  • Matsumoto, Nagano 390-8621, Japan
  • Hirakata, Osaka 573-1191, Japan
  • Chiyoda-ku, Tokyo 101-8309, Japan
  • Itabashi-ku, Tokyo 173-8606, Japan
  • Mitaka, Tokyo 181-8611, Japan
  • Shinjuku-ku, Tokyo 162-8666, Japan
  • Akita, 010-8543, Japan
  • Chiba, 260-8677, Japan
  • Fukuoka, 812-8582, Japan
  • Nagasaki, 852-8501, Japan
  • Osaka, 545-8586, Japan
  • Wakayama, 641-8510, Japan
  • Bytom, 41-902, Poland
  • Wroclaw, 50-556, Poland
  • Wroclaw, 51-124, Poland
  • Santiago de Compostela, A Coruña 15706, Spain
  • Oviedo, Asturias 33012, Spain
  • San Cugat Del Vallès, Barcelona 08190, Spain
  • Alicante, 03016, Spain
  • Barcelona, 8036, Spain
  • Pamplona, 31008, Spain
  • Valencia, 46015, Spain
09

References and documents

Publications

  • Nanegrungsunk O, Gu SZ, Bressler SB, Du W, Amer F, Moini H, Bressler NM. Correlation of Change in Macular Thickness With Change in Visual Acuity in Diabetic Macular Edema: Post Hoc Analysis of VISTA and VIVID Trials. J Vitreoretin Dis. 2022 Jul 27;6(4):284-289. doi: 10.1177/24741264221099429. eCollection 2022 Jul-Aug. PubMed 37007927 ↗
  • Valentim CCS, Singh RP, Du W, Moini H, Talcott KE. Time to Resolution of Diabetic Macular Edema after Treatment with Intravitreal Aflibercept Injection or Laser in VISTA and VIVID. Ophthalmol Retina. 2023 Jan;7(1):24-32. doi: 10.1016/j.oret.2022.07.004. Epub 2022 Jul 14. PubMed 35843487 ↗
  • Dhoot DS, Moini H, Reed K, Du W, Vitti R, Berliner AJ, Singh RP. Functional outcomes of sustained improvement on Diabetic Retinopathy Severity Scale with intravitreal aflibercept in the VISTA and VIVID trials. Eye (Lond). 2023 Jul;37(10):2020-2025. doi: 10.1038/s41433-022-02058-7. Epub 2022 Apr 19. PubMed 35440699 ↗
  • Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, Midena E, Kaiser PK, Terasaki H, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Zeitz O, Metzig C, Brown DM. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014 Nov;121(11):2247-54. doi: 10.1016/j.ophtha.2014.05.006. Epub 2014 Jul 8. PubMed 25012934 ↗
  • Brown DM, Schmidt-Erfurth U, Do DV, Holz FG, Boyer DS, Midena E, Heier JS, Terasaki H, Kaiser PK, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Zeitz O, Metzig C, Korobelnik JF. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies. Ophthalmology. 2015 Oct;122(10):2044-52. doi: 10.1016/j.ophtha.2015.06.017. Epub 2015 Jul 18. PubMed 26198808 ↗
  • Keating GM. Aflibercept: A Review of Its Use in Diabetic Macular Oedema. Drugs. 2015 Jul;75(10):1153-60. doi: 10.1007/s40265-015-0421-y. PubMed 26056030 ↗
  • Do DV, Gordon C, Suner IJ, Reed K, Moini H, Gibson A, Du W, Shah CP. Proliferative Diabetic Retinopathy Events in Patients With Diabetic Macular Edema: Post Hoc Analysis of VISTA and VIVID Trials. J Vitreoretin Dis. 2022 Jun 4;6(4):295-301. doi: 10.1177/24741264221093914. eCollection 2022 Jul-Aug. PubMed 37007930 ↗
  • Midena E, Gillies M, Katz TA, Metzig C, Lu C, Ogura Y. Impact of Baseline Central Retinal Thickness on Outcomes in the VIVID-DME and VISTA-DME Studies. J Ophthalmol. 2018 Mar 29;2018:3640135. doi: 10.1155/2018/3640135. eCollection 2018. PubMed 29785301 ↗
  • Staurenghi G, Feltgen N, Arnold JJ, Katz TA, Metzig C, Lu C, Holz FG; VIVID-DME and VISTA-DME study investigators. Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies. Br J Ophthalmol. 2018 Jul;102(7):954-958. doi: 10.1136/bjophthalmol-2017-310664. Epub 2017 Oct 19. PubMed 29051325 ↗
  • Wykoff CC, Marcus DM, Midena E, Korobelnik JF, Saroj N, Gibson A, Vitti R, Berliner AJ, Williams Liu Z, Zeitz O, Metzig C, Schmelter T, Heier JS. Intravitreal Aflibercept Injection in Eyes With Substantial Vision Loss After Laser Photocoagulation for Diabetic Macular Edema: Subanalysis of the VISTA and VIVID Randomized Clinical Trials. JAMA Ophthalmol. 2017 Feb 1;135(2):107-114. doi: 10.1001/jamaophthalmol.2016.4912. PubMed 28006063 ↗
  • Ziemssen F, Schlottman PG, Lim JI, Agostini H, Lang GE, Bandello F. Initiation of intravitreal aflibercept injection treatment in patients with diabetic macular edema: a review of VIVID-DME and VISTA-DME data. Int J Retina Vitreous. 2016 Jul 11;2:16. doi: 10.1186/s40942-016-0041-z. eCollection 2016. PubMed 27847634 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2011 to primary completion in Jun 2013, 24 months.

Results were first posted in Sep 2014, 1 year 3 months after primary completion. A results delay was requested in Mar 2014.

Of 167 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 23. This study's 24 months is above that.

Counting every sponsor, half of 230 studies reached it within 19 months; a quarter within 13 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2011
First posted
Apr 8, 2011
StartActual
May 9, 2011
Primary completionActual
Jun 3, 2013
CompletionActual
Mar 30, 2015
Results delay requested
Mar 31, 2014
Results first posted
Sep 9, 2014
Last update
Nov 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01331681
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Apr 8, 2011
Start date
May 9, 2011
Primary completion
Jun 3, 2013
Completion
Mar 30, 2015
Results posted
Sep 9, 2014
Last update
Nov 27, 2023

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion